Cancer

Investigators at Dana-Farber Cancer Institute have developed a platform for systematically discovering molecular glues that could become protein degradation drug candidates.

Researchers from Keio University have found that D-serine increases the growth of gastric cancer by creating an immunosuppressive and anti-inflammatory tumor microenvironment.

Drug resistance remains one of the greatest obstacles to successful treatment of gastric cancer, limiting the long-term effectiveness of the widely used chemotherapy drug cisplatin.

Earlier use of a targeted radionuclide therapy delays metastatic prostate cancer progression when administered as part of a trio of drugs, according to a phase 3 clinical trial led by Weill Cornell Medicine, NewYork-Presbyterian, Memorial Sloan Kettering Cancer Center and investigators at several other institutions worldwide.

A recent review explores the rapidly expanding field of ferroptosis-based therapy for prostate cancer, presenting ferroptosis as a promising strategy to overcome resistance in advanced and castration-resistant prostate cancer (CRPC).

A University of Oklahoma researcher has received a five-year, $2 million grant from the National Cancer Institute to investigate how pancreatic cancer uses cholesterol to survive chemotherapy.

Regularly checking in with patients with metastatic breast cancer by way of an app to enquire about their well-being – and responding promptly – can alleviate their debilitating fatigue and make their daily lives easier.

Researchers will hunt for antibodies in the blood of people who lived past 100, drank heavily, or smoked—but avoided cancer. The post Why Do Some People Never Get Cancer? The Answer May Be in Their Blood appeared first on SingularityHub.

Sydney Towle, a TikTok creator, shared her battle with cholangiocarcinoma, inspiring many with her candidness. Her journey reshaped online discussions about cancer and mortality, leaving a lasting impact.

Investigators at Dana-Farber Cancer Institute have developed a platform for systematically discovering molecular glues that could become protein degradation drug candidates. The platform could help drug developers dramatically expand the range of disease-related proteins that can be therapeutically targeted for elimination via protein degradation.

Experts at City of Hope, one of the nation's largest and most advanced cancer research and treatment organizations, are shining a spotlight on the risk of skin cancer faced by hematopoietic cell transplant (HCT) survivors, as well as the need for early detection.

Glioblastoma is the most aggressive form of brain cancer. It's difficult to treat because tumor cells infiltrate the surrounding brain tissue, making it hard for surgeons to remove the cancer completely without damaging healthy tissue. Treatment is further complicated by the blood-brain barrier, which limits how well drugs and radiation therapy reach the brain. All these factors contribute to a five-year survival rate of only around 7%.

A comprehensive new review article highlights the growing importance of the MYH9 gene as a central player in both cancer biology and inherited genetic conditions, offering fresh perspectives on its potential as a therapeutic target.

Sentinel-based lymph node procedures for endometrial cancer staging rise, while systematic lymphadenectomy rates fall by nearly half between 2018 and 2022.

Researchers query parents of children with cancer and clinicians on barriers and facilitators to participation in clinical trials.

A new review highlights the growing importance of circular RNAs (circRNAs) in addressing one of the most pressing challenges in modern oncology: treatment-related toxicity.

Barry Manilow cancelled a concert in Lexington, Kentucky, just 45 minutes before it was due to begin, sparking concern about his health as he continues to recover from early-stage lung cancer.

A growing body of evidence is reshaping how cancer is understood, placing the spotlight on intra-tumoral microbiota as powerful yet previously overlooked players within the tumor microenvironment.

To develop new targeted treatments for cancer, scientists need tissue models that accurately represent the genetic and molecular traits of the cancer they're studying.

Researchers at Baylor College of Medicine have developed a drug called CS18 that disrupts the ability of cancer cells to survive therapy. The findings, published in Science Advances, support exploring the possibility of using CS18 to treat human cancer in the future.

For nearly a decade, the Cancer Dependency Map, or DepMap, at the Broad Institute has helped scientists uncover new cancer dependencies - the genetic changes some cancers need to thrive that can potentially be targeted by new cancer drugs.

Digestion is hard on the cells that line the human gut, and they are constantly being shed and replaced. This renewal is driven by a population of tireless stem cells.

A growing body of evidence is reshaping how scientists and clinicians understand the role of cancer metabolism, placing the enzyme HMGCR at the center of a rapidly evolving therapeutic landscape.

A growing body of scientific insight is transforming how cancer treatment resistance is understood, highlighting a powerful cellular process known as lactylation as a central driver of disease progression and therapeutic failure.

Cancer cells have a voracious appetite for sugar—using it to fuel their rapid growth. This is why many scientists have tried to develop drugs that block cancer cells' metabolism by cutting off their sugar supply.

Researchers at The University of Texas MD Anderson Cancer Center have discovered that immunosuppressed patients with non-melanoma skin cancer are not missing the key cancer-fighting immune cells found in immunocompetent patients, but those cells – known as macrophages – have lost the ability to communicate effectively.

A new open resource of patient-derived cancer models has enabled researchers to create the first large-scale map of the genes that cancers rely on to survive, offering new routes for research into better and less toxic treatments for patients.

One family's experience reflects a growing issue in oncology: a hope that alternative therapies can succeed where conventional medicine has fallen short, a hope that can come with big risks.

Full multifactorial assessment flagged 34.8% of women who developed breast cancer within a decade, against 4.4% under current NICE criteria.

A major step forward in cancer immunotherapy is emerging through the growing development of dendritic cell vaccines, a highly targeted approach designed to harness the body's own immune system to fight tumors.

Particle chemoradiotherapy may show a better overall survival benefit in patients with locally advanced unresectable pancreatic cancer, per a single-arm meta-analysis.

A new review highlights the growing importance of miR-23b, a small but powerful regulator of gene expression, in shaping the development and progression of a wide range of cancers.

A little‑known group of hard-to-find immune cells could help transform cancer treatment, scientists at the University of Manchester’s Cancer Research UK Manchester Institute, have found.

Baseline clinical characteristics, rather than ERBB2 status, appeared to explain the survival differences observed between patients with ERBB2-low and ERBB2-null advanced gastric cancer.

Patients with high-risk ERBB2-negative breast cancer receive dual checkpoint blockade with cemiplimab and fianlimab in addition to standard neoadjuvant chemotherapy.

Liver metastases are among the most common and deadly forms of cancer spread. Now, researchers at VIB and KU Leuven, with international collaborators, have discovered how cancer cells exploit a fatty acid abundant in the liver to evade destruction by the immune system.

Cancer cells have a voracious appetite for sugar-using it to fuel their rapid growth. This is why many scientists have tried to develop drugs that block cancer cells' metabolism by cutting off their sugar supply.

Nature is the foremost international weekly scientific journal in the world and is the flagship journal for Nature Portfolio. It publishes the finest peer-reviewed research in all fields of science and technology on the basis of its originality, importance, interdisciplinary interest, timeliness, accessibility, elegance and surprising conclusions. Nature publishes landmark papers, award winning news, leading comment and expert opinion on important, topical scientific news and events that enable readers to share the latest discoveries in science and evolve the discussion amongst the global scientific community.

A 61-year-old grandmother, Susan Gehrke, was killed in a random attack by Dahseir Edward Jefferson, sparking outrage and calls for stricter sentencing for violent offenders with criminal histories.

A single blood test could help doctors predict how lung cancer patients will respond to treatment before therapy

Researchers followed 549,851 Korean children and found no statistically significant association between maternal diabetes and overall childhood cancer. The analysis linked maternal diabetes to an 81% higher relative risk of urinary tract cancer, but the absolute difference was only 37 additional cases per 100,000 offspring.

As we age, chronic inflammation-or "inflammaging"-increases throughout the body and weakens our ability to fight cancer.

New research from the University of Oklahoma demonstrates how an aggressive form of breast cancer co-opts the body's own immune system to attract nerves that fuel tumor growth.

Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the publication of a collaborative study in the journal npj Precision Oncology.

Chemotherapy-surviving ovarian cancer cells may release fructose to help neighboring tumor cells loosen, escape, and spread. The discovery suggests that sugary diets and cholesterol-lowering drugs could influence cancer progression, though the effects have not yet been confirmed in patients.

A specially engineered chewing gum reduced HPV by up to 93% and nearly eliminated two bacteria linked to head and neck cancer. The treatment preserved beneficial mouth bacteria, raising hopes for a safer and more affordable therapy.

Nature is the foremost international weekly scientific journal in the world and is the flagship journal for Nature Portfolio. It publishes the finest peer-reviewed research in all fields of science and technology on the basis of its originality, importance, interdisciplinary interest, timeliness, accessibility, elegance and surprising conclusions. Nature publishes landmark papers, award winning news, leading comment and expert opinion on important, topical scientific news and events that enable readers to share the latest discoveries in science and evolve the discussion amongst the global scientific community.

Oncology has shown quitting tobacco improves outcomes. Now the field must learn how to incorporate cessation treatment alongside other cancer treatments.

The National Institute for Health and Care Excellence (NICE) criteria used to decide who should be referred by GPs for further breast cancer risk assessment and specialist care misses up to 95% of women under 50 who will go on to develop the disease in the next 10 years, new research by researchers at the University of Cambridge and The Institute of Cancer Research, London, has found.

UCLA researchers have identified a promising strategy to make a new class of targeted cancer therapies more effective against one of the deadliest forms of prostate cancer, potentially overcoming treatment resistance that has limited their success.

A phase 2 study reported a longer median overall survival in patients receiving IV ascorbate with chemotherapy, although larger randomized trials are needed to confirm the finding.

MONDAY, Aug. 3, 2026 — Transgender individuals undergoing “top surgery” aren’t being provided adequate counseling about their future risk of breast cancer, a new study says.Top surgery — gender-affirming mastectomy — might appear to reduce or...

FDA has approved the radioligand in early disease, but whether it's better than other options is unknown.

Low arginine levels may allow cancer cells and viruses to slip past the immune system by reducing production of a crucial cellular warning protein. In mice, arginine-rich diets led to fewer colon tumors and milder viral infections, suggesting a simple supplement could have powerful therapeutic potential.

New research strengthens the case for using certain medications to help protect some patients from cardiac toxicity — and highlights major knowledge gaps.

Lower household income is linked to less treatment and worse survival in patients with localised pancreatic adenocarcinoma, a Dutch study shows.

PRL stands for Prolactin. It is a peptide hormone that is produced by the anterior pituitary gland. It

A trial tests whether 40Gy in 15 fractions over 3 weeks leads to more arm lymphedema than 50Gy in 25 fractions over 5 weeks.

A new path has opened toward stopping cancer-associated cachexia, a devastating complication that gradually wastes patients away.

Delta Goodrem returns to Strictly Come Dancing, inspired by her past cancer battle. The Australian singer aims to embrace new challenges and continue her musical evolution.

Cancer cells rely on powerful genetic switches to keep growth genes running at full speed, but that intense activity can damage their own DNA. The resulting breaks are repeatedly repaired, sometimes with small mistakes that allow new mutations to accumulate. Researchers believe this self-inflicted damage may help tumors evolve while also creating a potential target for new treatments.

A new study led by researchers at The University of Texas MD Anderson Cancer Center has identified a way to reshape the gut microbiome that can enhance the delivery of certain chemotherapies to tumors, offering a potential strategy to make nanoparticle-based cancer drugs more effective.

The amino acid arginine helps to keep the human body humming, most notably by synthesizing proteins that carry out a range of cellular processes.

Blood cancers that eventually worsen may carry detectable genetic warning signs years before patients develop serious symptoms. The findings could lead to earlier intervention while also helping doctors distinguish true cancer from harmless age-related blood changes.

Researchers at the Johns Hopkins Kimmel Cancer Center validated an artificial intelligence (AI)-powered blood test that accurately detected liver cancer in people from two geographically and biologically distinct populations and also uncovered the underlying biological signals that make the test effective.

A federal judge has allowed a Trump administration Medicaid policy requiring terminally ill patients to prove inability to work for exemptions, sparking legal challenges from Democratic states.

FRIDAY, July 31, 2026 — A woman’s genetic risk for breast cancer depends on her family history as well as the presence of cancer-causing mutations, a new study says.Breast cancer risk among women tested for BRCA gene mutations shifted depending on...

Enfortumab vedotin-induced cutaneous toxic effects are linked to improved survival in patients with advanced bladder cancer, a cohort study shows.

Patients with high-risk locally advanced rectal cancer were randomly assigned to receive doublet-LC TNT or conventional neoadjuvant chemoradiotherapy.

A British woman is the first to receive a pioneering ready-made cancer cell therapy, marking a significant milestone in developing faster, more accessible treatments for various cancers.

A US federal judge has upheld stricter Medicaid rules requiring documentation for exemptions, despite legal challenges and concerns over administrative burdens for patients with severe health conditions.

A combination of two immunotherapy drugs showed encouraging activity when added to standard chemotherapy given prior to surgery for patients with high-risk, early-stage HER2-negative breast cancer, according to phase 2 clinical trial results from the ongoing I-SPY2 clinical trial platform.

NYU Langone Health and Dana-Farber Cancer Institute have formed a strategic collaboration to co-develop Solavia Decision Suite, a next-generation oncology support platform designed to improve cancer care for patients and clinicians alike.

THURSDAY, July 30, 2026 — E-cigarettes could be reshaping the future of cancer in the United States, by offering people a less-toxic option than smoking, a new study argues.Smokers are increasingly switching to vaping and other forms of nicotine...

A new study from The Wistar Institute has uncovered an unexpected link between fructose - a common dietary sugar - and the spread of an aggressive form of ovarian cancer.

Nearly half of metastatic cutaneous squamous cell carcinoma cases arise from low-stage primary tumours, even when treatment is adequate, a nationwide analysis in Netherlands shows.

Two global reports offer new findings on incidence, mortality, and disparities, with implications for US oncologists.

Medicare coverage of next-generation sequencing may have spurred an increase in the number of patients receiving genomic tests. But uptake remains low.

A phase 2 trial finds that adding a modest radiation boost improves 9-year survival without increasing toxicity, despite no improvement in pathologic complete response.

Patients with deficient DNA mismatch repair (dMMR) or microsatellite instability-high (MSI-H) metastatic colorectal cancer experienced a 58% reduction in the risk of disease progression or death when treated with atezolizumab plus modified FOLFOX6 and bevacizumab compared with atezolizumab alone, according to results from the NRG-GI004/SWOG S1610 COMMIT trial published recently in the Journal of Clinical Oncology.

After Medicaid expansion, early-stage diagnosis and 3-year survival improve among Americans with lung cancer, primarily those living in nonurban areas.

Researchers developed Oncoformer, a multimodal transformer that analyzes longitudinal health records and chest X-rays to classify cancer, predict diagnoses up to one year in advance, infer tumor stage, and forecast treatment response and recurrence risk. Validation across large independent cohorts showed strong performance, although prospective trials in diverse, average-risk populations are needed before clinical use.

A new artificial intelligence (AI) tool developed by La Trobe University researchers could help predict which stage-two bowel cancer patients are at risk of relapse, in an advance that could ultimately lead to thousands getting life-saving treatment earlier.

Cancer cells survive by hiding from the immune system's surveillance. A KAIST research team has developed a new anticancer platform that makes cancer cells send out their own danger signal—prompting immune cells to attack—while simultaneously delivering gene therapy.

Cancer cells survive by hiding from the immune system's surveillance. A KAIST research team has developed a new anticancer platform that makes cancer cells send out their own danger signals—prompting immune cells to attack—while simultaneously delivering gene therapy. The approach is expected to offer a new treatment strategy that combines cancer immunotherapy and gene therapy in a single nanoparticle.

Enhertu, Piqray, and Trodelvy moved closer to broader EU indications after CHMP backed new first-line combinations and expanded biomarker-based use in breast cancer.

Many experts consider prostate cancer one of immunotherapy’s biggest disappointments. But a handful of patients don’t fit that narrative, and researchers are starting to uncover why.

A 23-year analysis of hypertensive patients reveals differing cancer incidence patterns between two widely prescribed blood pressure medication classes, with variations across specific malignancies.

The vast majority of cases begin in the fallopian tubes — and removing them can reduce the risk by nearly 80 percent.

A Canadian study shows higher cancer incidence among children who live in affluent and residentially stable neighborhoods.

Artificial intelligence developed by researchers at UCL has revealed a promising combination of cancer treatments that could help patients with locally advanced rectal cancer live longer.

A new multi-center clinical study is shedding light on a potential new approach for patients with advanced kidney cancer, offering measurable clinical responses alongside a clearer view into how the disease operates beneath the surface.